Real-world Short-term Effectiveness of Ustekinumab in Crohn’s Disease: Results from a Multicenter, Prospective Study in China
Qian Cao, Chunxiao Chen, Xiang Gao, Yan Chen, Naizhong Hu, Jie Liang, Kaichun Wu
Abstract
Lay Summary Ustekinumab effectively induced a clinical response and clinical remission, with remission rates superior to those in the UNITI-1 study. Ustekinumab is more effective in biologic-naive patients with Crohn’s disease than those who were not responsive to anti–tumor necrosis factor treatment.
Topics & Concepts
UstekinumabMedicineCrohn's diseaseInternal medicineDiseaseCrohn diseaseGastroenterologyAdalimumabInflammatory Bowel DiseaseImmunodeficiency and Autoimmune DisordersEosinophilic Esophagitis